Companies / BOC Sciences / Ranibizumab
BOC Sciences

Ranibizumab | BOC Sciences

Ranibizumab is a monoclonal antibody fragment (Fab) which could inhibit angiogenesis via suppressing vascular endothelial growth factor (VEGF) A. In Dec. 2016, it was approved for the treatment of the age-related macular degeneration (AMD) and visual impairment caused by choroidal neovascularization (CNV).

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.